LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...

A cyberattack on Synnovis has been linked to a patient's death at King's College Hospital, marking a serious hacking ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...